TGF-β1 Protects Hippocampal Neurons Against Degeneration Caused by Transient Global Ischemia: Dose-Response Relationship and Potential Neuroprotective Mechanisms
Abstract
Background and Purpose Transforming growth factor-β1 (TGF-β1) has been shown to rescue cultured neurons from excitotoxic and hypoxic cell death and to reduce infarct size after focal cerebral ischemia in mice and rabbits. The present study investigated the effects of TGF-β1 in a different pathophysiological setting and the delayed neuronal death of hippocampal pyramidal cells after transient global ischemia in rats, and evaluated the potential mechanisms of the neuroprotective activity of TGF-β1. Methods Transient forebrain ischemia was induced in male adult Wistar rats with bilateral occlusion of both common carotid arteries combined with systemic hypotension for 10 minutes. Seven days after ischemia, brains were perfusion-fixed and stained for histological evaluation. TGF-β1 or vehicle was injected intracerebroventricularly (ICV; 0.5, 4, and 50 ng) or intrahippocampally (4 ng) 1 hour before ischemia. For in vitro studies, hippocampal neurons were derived from E17 rat embryos and cultured for 10 to 14 days. Cells were exposed to (1) S -nitrosocysteine (SNOC; 30 μmol/L) to induce nitric oxide–induced oxidative injury and (2) staurosporine (0.03 μmol/L) to induce apoptotic cell death. Results Transient forebrain ischemia caused extensive degeneration of CA1 hippocampal pyramidal cells in vehicle-treated control animals. Ischemic injury was not significantly reduced after ICV administration of 0.5 ng TGF-β1 (71±7% damaged neurons versus 84±3% in vehicle-treated controls; n=9 and 11, respectively; P =.07, Mann-Whitney U test). Administration of 4 ng TGF-β1 reduced the percentage of damaged CA1 pyramidal cells from 71±10% in controls to 52±7% in TGF-β1–treated animals (n=11 and 12, respectively; P =.04). TGF-β1 (4 ng) also produced significant protection when injected directly into the hippocampal tissue. In contrast, ICV administration of 50 ng TGF-β1 failed to show a protective effect in two separate sets of experiments. In vitro, a 24-hour pretreatment of the cultured hippocampal neurons with TGF-β1 (0.1 to 10 ng/mL) significantly inhibited both nitric oxide and staurosporine neurotoxicity. Posttreatment with TGF-β1 (10 ng/mL) also inhibited staurosporine neurotoxicity but actually potentiated nitric oxide–induced neuronal injury. Conclusions We demonstrated that TGF-β1 in a surprisingly low dose range has the capacity to reduce injury to CA1 hippocampal neurons caused by transient global ischemia in rats. This protective action could well be associated with the antioxidative and antiapoptotic effects of TGF-β1 demonstrated in vitro.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TGF-β and their receptors are expressed at low levels by both neurons and glial cells, and their expression is upregulated in response to a wide range of neuronal insults and during aging.
“TGF-β and their receptors are expressed at low levels by both neurons and glial cells42,43, and their expression is upregulated in response to a wide range of neuronal insults and during aging44,45.”
From Identification of a unique TGF-β–dependent molecular and functional signature in microglia (2014) · cites this paper as [44]
Cites
Biochemistry of nitric oxide and its redox-activated forms
Stamler, J. S., Singel, D. J., & Loscalzo, J. (1992) · Science · doi:10.1126/science.1281928 · Cited by 2,744 · see citing works
Amelioration of delayed neuronal death in the hippocampus by nerve growth factor
Shigeno, T., Mima, T., Takakura, K., Graham, D., Kato, G., Hashimoto, Y., & Furukawa, S. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-09-02914.1991 · Cited by 333 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · see citing works
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487 · see citing works
The role of astroglia in neuroprotection
Bélanger, M., & Magistretti, P. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/mbelanger · Cited by 396 · see citing works
Apoptotic and antiapoptotic mechanisms in stroke
Mattson, M. P., Culmsee, C., & Yu, Z. F. (2000) · Cell and Tissue Research · doi:10.1007/s004419900154 · Cited by 318 · see citing works
Macrophages prevent hemorrhagic infarct transformation in murine stroke models
Gliem, M., Mausberg, A. K., Lee, J., Simiantonakis, I., van Rooijen, N., Hartung, H., & Jander, S. (2012) · Annals of Neurology · doi:10.1002/ana.23529 · Cited by 284 · see citing works
Astrocytes as a Source for Extracellular Matrix Molecules and Cytokines
Wiese, S., Karus, M., & Faissner, A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00120 · Cited by 262 · see citing works
The Choroid Plexus in Healthy and Diseased Brain
Kaur, C., Rathnasamy, G., & Ling, E.-A. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv030 · Cited by 176 · see citing works
Chen, J.-H., Ke, K.-F., Lu, J.-H., Qiu, Y.-H., & Peng, Y.-P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116549 · Cited by 151 · see citing works
TGF-β Pathway as a Potential Target in Neurodegeneration and Alzheimers
Wyss-Coray, T. (2006) · Current Alzheimer Research · doi:10.2174/156720506777632916 · Cited by 85 · see citing works
Zhang, Z., Bassam, B., Thomas, A. G., Williams, M., Liu, J., Nance, E., Rojas, C., Slusher, B. S., & Kannan, S. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.010 · Cited by 84 · see citing works
- Authors
- Henrich-Noack, P., Prehn, J. H. M., & Krieglstein, J.
- Affiliations
- the Department of Pharmacology and Toxicology, Philipps-University, Marburg, Germany.
- Venue
- Stroke
- Published
- 1996-09
- Volume
- 27
- Issue
- 9
- Pages
- 1609-1615
- ISSN
- 0039-2499
- 1524-4628
- Cited by
- 170
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review